[go: up one dir, main page]

WO2004111088A3 - Nouveau facteur angiogenique et ses inhibiteurs - Google Patents

Nouveau facteur angiogenique et ses inhibiteurs Download PDF

Info

Publication number
WO2004111088A3
WO2004111088A3 PCT/EP2004/006265 EP2004006265W WO2004111088A3 WO 2004111088 A3 WO2004111088 A3 WO 2004111088A3 EP 2004006265 W EP2004006265 W EP 2004006265W WO 2004111088 A3 WO2004111088 A3 WO 2004111088A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
angiogenic factor
sep
pharmaceutical compositions
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/006265
Other languages
English (en)
Other versions
WO2004111088A2 (fr
Inventor
Hendrik Gille
Beate Gawin
Rolf Schaefer
Stephan Hess
Christian Korherr
Irene Boche
Theresia Walter
Andreas Gnirke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xantos Biomedicine AG
Original Assignee
Xantos Biomedicine AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xantos Biomedicine AG filed Critical Xantos Biomedicine AG
Priority to EP04739768A priority Critical patent/EP1636258A2/fr
Publication of WO2004111088A2 publication Critical patent/WO2004111088A2/fr
Publication of WO2004111088A3 publication Critical patent/WO2004111088A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un nouveau facteur angiogénique, SEP, ainsi que des dérivés solubles de celui-ci, et leur utilisation dans des compositions pharmaceutiques ou diagnostiques.
PCT/EP2004/006265 2003-06-10 2004-06-09 Nouveau facteur angiogenique et ses inhibiteurs Ceased WO2004111088A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04739768A EP1636258A2 (fr) 2003-06-10 2004-06-09 Nouveau facteur angiogenique et ses inhibiteurs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47747003P 2003-06-10 2003-06-10
US60/477,470 2003-06-10
US50338803P 2003-09-16 2003-09-16
US60/503,388 2003-09-16

Publications (2)

Publication Number Publication Date
WO2004111088A2 WO2004111088A2 (fr) 2004-12-23
WO2004111088A3 true WO2004111088A3 (fr) 2005-02-10

Family

ID=33555461

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2004/006265 Ceased WO2004111088A2 (fr) 2003-06-10 2004-06-09 Nouveau facteur angiogenique et ses inhibiteurs
PCT/EP2004/006270 Ceased WO2004111085A1 (fr) 2003-06-10 2004-06-09 Facteur angiogenique et son utilisation medicale

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006270 Ceased WO2004111085A1 (fr) 2003-06-10 2004-06-09 Facteur angiogenique et son utilisation medicale

Country Status (2)

Country Link
EP (1) EP1636258A2 (fr)
WO (2) WO2004111088A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007054042A (ja) * 2005-07-26 2007-03-08 Japan Science & Technology Agency インターフェロン誘導分子ｉｐｓ−１
EP1892528A1 (fr) * 2006-08-25 2008-02-27 Institut Pasteur Utilisation d'un agent modulateur de la production de l'interféron, interagissant avec le pbd de plk
US11224665B2 (en) * 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006552A2 (fr) * 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees exprimees dans le cerveau
WO2002053737A1 (fr) * 2000-12-28 2002-07-11 Asahi Kasei Kabushiki Kaisha Gene d'activation de nf-kb
WO2003048202A2 (fr) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Gène activant le facteur nucléaire kappa b

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006552A2 (fr) * 1997-08-01 1999-02-11 Genset Est 5' pour proteines secretees exprimees dans le cerveau
WO2002053737A1 (fr) * 2000-12-28 2002-07-11 Asahi Kasei Kabushiki Kaisha Gene d'activation de nf-kb
WO2003048202A2 (fr) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Gène activant le facteur nucléaire kappa b

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI; 30 January 2003 (2003-01-30), STRAUSBERG RL ET AL.: "Homo sapiens KIAA1271 protein, mRNA (cDNA clone MGC:50830 IMAGE:5751684), complete cds.", XP002297873, Database accession no. BC0044952 *
DATABASE EMBL EBI; 4 January 2002 (2002-01-04), STRAUSBERG RL ET AL.: "Mus musculus RIKEN cDNA D430028G21 gene, mRNA (cDNA clone MGC:25836 IMAGE:4190175), complete cds.", XP002297872, Database accession no. BC020006 *
MATSUDA AKIO ET AL: "Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.", ONCOGENE. 22 MAY 2003, vol. 22, no. 21, 22 May 2003 (2003-05-22), pages 3307 - 3318, XP002297871, ISSN: 0950-9232 *
THOMPSON J D: "Applications of antisense and siRNAs during preclinical drug development", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 17, 1 September 2002 (2002-09-01), pages 912 - 917, XP002236964, ISSN: 1359-6446 *

Also Published As

Publication number Publication date
WO2004111085A1 (fr) 2004-12-23
WO2004111088A2 (fr) 2004-12-23
EP1636258A2 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
IL169469A (en) Folic acid derivatives containing disulfide bonds, their pharmaceutical compositions and their use
HUP0400194A3 (en) Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
AU2003289440A1 (en) Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
AU2003293649A1 (en) Novel xanthine derivatives, the production and the use thereof in the form of drugs
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
EP2415760A3 (fr) Antagonistes du CCR-9
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
IL181634A (en) Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL177496A0 (en) Amido-substituted hydroxy -6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
HUP0400156A3 (en) Pyrrolidine derivatives as factor xa inhibitors, their preparation and pharmaceutical compositions containing them
WO2004112771A8 (fr) Compositions pharmaceutiques comprenant un antihistaminique et un stimulant et leur utilisation
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
IL181216A (en) 5, 3-SICO-4-NORKOLSTAN DERIVATIVES AND PHARMACEUTICAL COMPONENTS CONTAINING @ THEM
AU2007310767A1 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004739768

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004739768

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2004739768

Country of ref document: EP